|Toxiciy Grade:||4||City/State/Province:||Durham, North Carolina|
|Treatments:||Chemotherapy, Radiation||Hospital:||Duke University Medical Center|
Patients: This Phase I study involved 6 patients (4 men, 2 women, median age 71) with rectal cancer and 10 patients (6 men, 4 women, median age 65) with pancreatic cancer.
Treatment: Treatment consisted of radiotherapy and two drugs: gefitinib (a biological agent) and capecitabine (chemotherapy).
Toxicity: Grade 3-4 toxicities included diarrhea, nausea/vomiting, dehydration, and anorexia.
Results: The median overall survival was not reported. The authors concluded, "The combination of gefitinib, capecitabine, and radiation in pancreatic and rectal cancer patients resulted in significant toxicity."
Support: Several authors disclosed prior relationships as consultants, honoraria recipients, and grant recipients related to Roche or AstraZeneca. Roche manufactures and/or markets capecitabine. AstraZeneca manufactures and/or markets gefitinib.
Correspondence: Brian G. Czito